A Phase 2 interventional study of JTT-705 600 mg and simvastatin 40 mg and Placebo and simvastatin 40 mg in Dyslipidemia, sponsored by Akros Pharma Inc.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-06-03.
Sponsored by Akros Pharma Inc. · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with simvastatin 40 mg in patients with low HDL
1,073 studies on the registry are indexed under Dyslipidemias; 158 are open to participants now.
This study's enrollment of 92 is close to the median of 99 across 842 interventional studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Akros Pharma Inc. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
JTT-705 600 mg and simvastatin 40 mg
Drug: JTT-705 600 mg and simvastatin 40 mg
Placebo and simvastatin 40 mg
Drug: Placebo and simvastatin 40 mg
* JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment * Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments
* Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments * Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
% change from baseline in HDL-C; inhibition of CETP activity
Time frame: 4-weeks
% change from baseline in LDL-C and TC/HDL-C
Time frame: 4-weeks
Plasma concentration of JTT-705
Time frame: 4-weeks
This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Akros Pharma Inc.